Positions

Overview

  • Dr. Sung is originally from Houston, TX and completed his undergraduate degree in Neuroscience from Vanderbilt University. He completed medical school at UT-Southwestern Medical Center at Dallas and completed neurology residency and movement disorders fellowship at UAB. He joined faculty in the UAB Department of Neurology, Division of Movement Disorders and has the rank of Associate Professor with Tenure. He is the Director of the UAB Huntington's Disease Clinic, Co-Director of the UAB School of Medicine Neuroscience Module, and is the Director of the Birmingham VAMC Deep Brain Stimulation Program. Dr. Sung received the President's Award for Excellence in Teaching in 2019 and received the A.B. Baker Outstanding Teacher of the Year Award from the American Academy of Neurology for 2021. He serves on the National Board of Trustees of the Huntington's Disease Society of America, currently serving as Chair of the Board from 2021-23.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2023 Connectomic Basis for Tremor Control in Stereotactic Radiosurgical ThalamotomyAmerican Journal of Neuroradiology.  44:157-164. 2023
    2022 The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension StudyCNS Drugs.  36:1207-1216. 2022
    2021 Intermittent theta burst stimulation (iTBS) for treatment of chronic post-stroke aphasia: Results of a Pilot randomized, double-blind, sham-controlled trial 2021
    2020 Safety and tolerability of srx246, a vasopressin 1a antagonist, in irritable huntington’s disease patients—a randomized phase 2 clinical trialJournal of Clinical Medicine.  9:1-14. 2020
    2019 Involuntary Movements with Abnormal Brain Imaging Led to the DiagnosisJournal of Pediatrics.  213:246-246.e1. 2019
    2018 Physician perceptions of pharmacologic treatment options for chorea associated with Huntington disease in the United StatesCurrent Medical Research and Opinion.  34:643-648. 2018
    2018 Review of deutetrabenazine: A novel treatment for chorea associated with Huntington’s diseaseDrug Design, Development and Therapy.  12:313-319. 2018
    2018 A feasibility study of combined intermittent theta burst stimulation and modified constraint-induced aphasia therapy in chronic post-stroke aphasiaRestorative Neurology and Neuroscience.  36:503-518. 2018
    2018 Retrospective Analysis of Healthcare Resource Use, Treatment Patterns, and Treatment-related Events in Patients with Huntington's Disease-associated Chorea Initiated on Tetrabenazine.Journal of Health Economics and Outcomes Research.  6:15-24. 2018
    2018 Tetrabenazine Treatment Patterns and Outcomes for Chorea Associated with Huntington Disease: A Retrospective Chart ReviewJournal of Huntington's Disease.  7:345-353. 2018
    2017 Safety of converting from tetrabenazine to deutetrabenazine for the treatment of ChoreaJAMA Neurology.  74:977-982. 2017
    2016 Effect of deutetrabenazine on chorea among patients with huntington disease : A randomized clinical trialJournal of the American Medical Association.  316:40-50. 2016
    2013 The relationship between clinical phenotype and early staged bilateral deep brain stimulation in Parkinson disease: Clinical articleJournal of Neurosurgery.  119:1530-1536. 2013
    2013 Nonmotor symptoms in parkinson's disease. Expanding the view of parkinson's disease beyond a pure motor, pure dopaminergic problemNeurologic Clinics.  31. 2013
    2012 Isolated CNS Whipple disease with normal brain MRI and false-positive CSF 14-3-3 protein: A case report and review of the literatureBrain and Behavior.  2:838-843. 2012
    2011 Low medication adherence and the incidence of stroke symptoms among individuals with hypertension: The REGARDS studyJournal of the CardioMetabolic Syndrome.  13:479-486. 2011
    2011 Sensitivity and specificity of stroke symptom questions to detect stroke or transient ischemic attackNeuroepidemiology.  36:100-104. 2011
    2009 Images from headache: BlastomycosisHeadache.  49:461-462. 2009
    2007 Acute respiratory failure complicating intracranial hypotensionHeadache.  47:1340-1341. 2007
    2004 Elevated plasma homocysteine level in patients with Parkinson disease: Motor, affective, and cognitive associationsJAMA Neurology.  61:865-868. 2004
    1998 A cytokine cascade including prostaglandin E2, IL-4, and IL-10 is responsible for UV-induced systemic immune suppressionJournal of Immunology.  160:3783-3789. 1998

    Chapter

    Year Title Altmetric
    2016 Pharmacology of dopaminergic neurotransmission 2016

    Research Overview

  • Huntington's Disease
  • Principal Investigator On

  • 2013 HDSA Center of Excellence Grant Application  awarded by Huntington's Disease Society of America, Inc.
  • 2014 HDSA Center of Excellence Grant  awarded by Huntington's Disease Society of America, Inc.
  • 2015 Huntington's Disease Society of America Centers of Excellence Program  awarded by Huntington's Disease Society of America, Inc.
  • An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects with Huntington's Disease (HD)  awarded by MASSACHUSETTS GENERAL HOSPITAL
  • Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)  awarded by MASSACHUSETTS GENERAL HOSPITAL
  • Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)  awarded by MASSACHUSETTS GENERAL HOSPITAL
  • Development of Assessments for Later Stage Huntington's Disease: UHDRS Structured Interview of Function and HD Clinical Status Questionnaire  awarded by CHDI Foundation
  • Enroll-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort A CHDI Foundation Project  awarded by CHDI Foundation
  • Huntington's Disease Society of America Centers of Excellence Program 2018  awarded by Huntington's Disease Society of America, Inc.
  • Huntington's Disease Society of America Centers of Excellence Program 2021  awarded by Huntington's Disease Society of America, Inc.
  • Private Grant  awarded by AUSPEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by AUSPEX PHARMACEUTICALS, INC.
  • Private Grant  awarded by Pfizer Pharmaceuticals
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group
  • Private Grant  awarded by VACCINEX, INC.
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by NEUROCRINE BIOSCIENCES INC
  • Private Grant  awarded by NEUROCRINE BIOSCIENCES INC
  • Private Grant  awarded by UNIQURE BIOPHARMA B.V.
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Validation of the Virtual Unified Huntington’s Disease Rating Scale (vUHDRS®)  awarded by Huntington Study Group
  • Investigator On

  • 2012 HDSA Center of Excellence Grant  awarded by Huntington's Disease Society of America, Inc.
  • Clinician-input Study: How the Fox Wearable Companion Mobile Application can Influence Treatment and Care (CIS-PD)  awarded by Fox (Michael J.) Foundation for Parkinson's Research
  • Fox Investigation for New Discovery of Biomarkers (BioFIND)  awarded by Fox (Michael J.) Foundation for Parkinson's Research
  • Functional Change in Mild Cognitive Impairment  awarded by National Institute on Aging/NIH/DHHS
  • Noninvasive Biomarkers to Advance Emerging DBS Electrode Technologies in Parkinson’s Disease  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Post-Stroke Aphasia and rTMS Treatment (PART) Study  awarded by National Institute of Child Health and Human Development/NIH/DHHS
  • Private Grant  awarded by MedImmune
  • Private Grant  awarded by AVANIR PHARMACEUTICALS, INC.
  • Private Grant  awarded by BOSTON SCIENTIFIC CORPORATION
  • Private Grant  awarded by ANNEXON BIOSCIENCES INC
  • Private Grant  awarded by PTC THERAPEUTICS, INC.
  • Private Grant  awarded by SAGE THERAPEUTICS
  • The Edmond J. Safra Visiting Nurse Faculty Program at Parkinson's Foundation  awarded by National Parkinson Foundation, Inc.
  • The Edmond J. Safra Visiting Nurse Faculty Program at the Parkinson Disease Foundation  awarded by National Parkinson Foundation, Inc.
  • The Parkinson's Progression Marker's Initiative (PPMI)  awarded by Fox (Michael J.) Foundation for Parkinson's Research
  • The Parkinson’s Progression Markers Initiative (PPMI) 2.0 Clinical - Establishing a Deeply Phenotyped PD Cohort  awarded by Fox (Michael J.) Foundation for Parkinson's Research
  • The Parkinson’s Progression Markers Initiative (PPMI) 2.0 Clinical - Establishing a Deeply Phenotyped PD Cohort  awarded by Fox (Michael J.) Foundation for Parkinson's Research
  • Education And Training

  • John Peter Smith Hospital, Internship
  • John Peter Smith Hospital, Internship
  • UAB Hospital, Residency
  • University of Alabama at Birmingham Neurology, Residency
  • University of Alabama at Birmingham, Postdoctoral Fellowship
  • Doctor of Medicine, University of Texas System : Southwestern Medical Center at Dallas 2005
  • Full Name

  • Victor Sung